Chimeric receptors bearing ligand recognition domains linked to signaling regions from the T-cell receptor can redirect T lymphocytes against non-MHC-restricted targets. Cytolytic T lymphocytes (CTL) expressing these chimeric receptors are being tested in preclinical and clinical trials for activity in cancer, infectious diseases and autoimmunity. The chimeric receptors may incorporate antigenic epitopes previously unrecognized by the immune system. Whether a receptorspecific antibody response develops to these neoantigens and whether such a response inhibits therapeutic cell activity is unknown. We hypothesized that upon engagement of a chimeric receptor-specific B cell, receptor-modified CTL will be activated, lysing the B cell and inducing tolerance to the chimeric receptor rather than immunity. We demonstrate that receptor-modified CTL are indeed stimulated by cognate receptor-specific B cells, proliferate and produce cytokines in response and kill the B cells in vitro and in vivo. However, this is insufficient to induce full B-cell tolerance. Modified CTL induce a chimeric receptor-specific antibody response independent of any other source of antigen. Nevertheless, the CTL retain substantial activity even in the presence of saturating doses of receptor-specific antibody. Thus antichimeric receptor antibody responses need to be considered in the clinical use of chimeric receptor-modified T cells. However, the inhibitory activity of these antibodies may in cases be limited.
Introduction
Adoptively transferred antigen-specific T lymphocytes have demonstrated potential in the treatment of cancer, infectious diseases and autoimmunity. [1] [2] [3] The usefulness of transferred T lymphocytes is however limited by inherent constraints in the T-cell repertoire and in recognition properties of the T-cell receptor (TCR). T cells with too high or too low an avidity for self antigens are culled developmentally or in the periphery. 4 This limits the TCR repertoire's recognition range. TCR further can only recognize antigenic ligands in the context of major histocompatability complex (MHC) molecules and typically have very low affinities for antigen, 100-to 1000-fold lower than immunoglobulin (Ig) molecules. 5 Thus T lymphocytes are blind to antigens that do not associate with MHC, are expressed on cells that lack or have downregulated MHC or that have too low an avidity to effectively stimulate the T cell.
One way to bypass these limitations is to endow T cells with engineered receptors incorporating enhanced ligand recognition properties. [6] [7] [8] [9] Chimeric surrogate TCR link novel ligand recognition domains with signaling tails derived from the immune tyrosine activation motifbearing TCR-z or CD3 chains. Most commonly the receptors are transgenically expressed on T cells (receptor-modified T cells; RMTC) by retroviral transduction. When the chimeric receptor engages its target, it transduces a signal through the signaling domain, activating the RMTC.
RMTC may be used for various therapeutic purposes. Chimeric receptors incorporating single chain Fv (scFv) specific for tumor antigens have been successfully used in a number of model systems to redirect cytolytic T lymphocytes (CTL) against tumor targets. MHC or MHC-peptide conjugates linked to TCR-signaling domains can redirect RMTC against antigen-specific T lymphocytes, thereby ameliorating autoimmune disease. [10] [11] [12] Similarly, cells expressing CD4-z conjugates have been used to target human immunodeficiency virus (HIV)-infected cells, which bind to CD4 through HIV gp120. 13 Thus chimeric surrogate TCR are malleable structures that can be used to redirect immune responses. Phase I clinical trials have failed to reveal toxicity of RMTC. [14] [15] [16] One potential limitation in the use of RMTC is the development of an immune response directed against the chimeric receptor, which is a novel structure unfamiliar to the host. Indeed, green fluorescent protein (GFP) expressed on genetically modified cells has been shown to be capable of invoking specific immune responses. 17 However, unlike other adoptive immunotherapy models, it would be anticipated that some RMTC will be resistant to B-cell immunity. T cells and B cells closely interact within the lymphoid compartment as T cells survey B cells for surface presentation of cognate antigen. 18 If an RMTC that is a CTL recognizes a B cell-specific for its chimeric receptor, the RMTC should be stimulated and lyse that receptor-specific B cell. Thus RMTC would be expected to tolerize chimeric receptorspecific B cells. In the absence of tolerance induction, receptor-specific B cells may be stimulated. An antibody (Ab) response may then develop against the chimeric receptor that could competitively block ligand recognition by it or promote RMTC clearance through Abdependent mechanisms.
To better define the interaction between RMTC and B cells, we have created two chimeric receptors that direct RMTC against antigen-specific B cells. One of these links hen egg lysozyme (HEL) to the cytoplasmic signaling domains of CD28 and z. The second links the class I MHC K b to an identical signaling region. We show that RMTC expressing these receptors recognize HEL-or K b -specific B lymphocytes and efficiently eliminate antigenspecific B cells both in vitro and in vivo. Interestingly, the RMTC are able to target cognate transgenic (Tg) B cells through their Ig receptor even in the presence of saturating quantities of the same chimeric receptorspecific Ig in soluble form. Yet, despite these capabilities, the RMTC are unable to fully contain the B-cell immune response, and adoptive transfer of HEL-CD28-z RMTC induces specific antibodies against native chimeric receptor. Our results illustrate both the potency of RMTC, which are able to eliminate specific targets even in the presence of blocking Ab, and the resilience of the host-immune response, which is able to nevertheless produce chimeric receptor-specific antibodies. The development of chimeric receptor-specific immune responses after treatment with RMTC exposes one potential limitation in their therapeutic application.
Results
Design of the K b -CD28-z and HEL-CD28-z constructs are shown (Figures 1a and b) . The HEL protein was linked to the hinge and transmembrane (TM) domains of CD8, whereas the K b receptor included the endogenous K b TM domain. The addition of the CD28 signaling tail to TCR-z in the signaling domain has been shown to enhance RMTC survival and function in several studies. [19] [20] [21] We also inserted a L-G mutation at the N terminus of the CD28 sequence because studies of the K b -CD28-z construct showed this to enhance expression by disrupting a potentially cryptic dileucine motif. 22 Receptor cDNA was subcloned into a murine stem cell virus (MSCV)-driven retroviral expression vector that included an internal ribosome entry site-linked GFP (MSCV-I-GFP), and recombinant retrovirus was used to transduce stimulated primary T lymphocytes. Transduction efficiencies of B10-50% were routinely observed. CD8 + GFP + cells were flow cytometrically purified prior to analyses. Anti-HEL or K b Ab staining verified HEL-CD28-z and K b -CD28-z receptor expression, which correlated with the expression of GFP (Figures 1c and d) .
To determine whether the HEL-CD28-z receptor could redirect T-cell function, we analyzed the functional consequences of chimeric receptor triggering. We used MD-4 Tg B lymphocytes as targets for the HEL-CD28-z RMTC. 23 Studies of CTL function have shown that different T-cell effector functions require quantitatively different stimuli through the TCR, with cytolysis most easily triggered, followed by cytokine production and then proliferation. 24 Coculture of MD-4 Tg B cells triggered the release of interferon (IFN)-g from RMTC but not control vector-transduced T cells (Figure 2a) . Production was specific, and was not seen when non-Tg B cells were used to stimulate the RMTC. Similarly, MD-4 B cells specifically induced the proliferation of resting HEL-CD28-z RMTC (Figure 2b ).
To determine if the HEL-CD28-z RMTC could lyse HEL-specific B cells, MD-4 splenocytes (B50% B cells) were cocultured with purified CD8 + RMTC at an B1:1 ratio. Residual HEL-specific B-cell numbers were assessed at 6 h using quantitative flow cytometry, staining both with the pan-B-cell marker B220 and with labeled HEL antigen. Vector-transduced CTL were unable to kill the MD-4 cells (Figures 2c and d) . In contrast, potent and specific cytolysis, with virtually complete elimination of the HEL + target cell population, was observed after treatment with HEL-CD28-z RMTC. Of note, a slightly greater loss of HEL + than B220 + cells was seen (Figure 2d ; B220 + : 2566770 for control and 203763 for HEL-CD28-z RMTC, HEL + : 24987144 for control and 11716 for HEL-CD28-z RMTC). This likely reflects the presence of some B220 + Tg B cells that do not bind HEL. However, it is not possible to exclude the presence of small numbers of B220 + B cells that were not killed by the RMTC but have downmodulated their Tg BCR after encountering HEL Ag in the culture. These results demonstrate that the HEL-CD28-z receptor is functional, and when expressed on CTL is able to redirect their function against antigenspecific B lymphocytes. Signaling through the HEL-CD28-z receptor, as through TCR, mediates cytolysis, cytokine production and proliferation.
We were next interested in determining whether the RMTC could similarly recognize and eliminate target B cells in vivo. To test this, MD-4 Tg splenocytes were adoptively transferred into syngeneic C57BL/6 Rag À/À recipient mice. Flow cytometrically purified CD8 + RMTC were then administered and 48 h later lymphoid organs were analyzed for residual B lymphocytes. Because the host lacked endogenous B cells, the transferred B cells could be detected by staining either with B220 or the labeled HEL ligand. Whereas mice treated with control vector-transduced T cells retained significant numbers of MD-4 B cells, those treated with HEL-CD28-z RMTC contained few residual B lymphocytes (Figure 3 ). Therefore adoptively transferred RMTC can identify and eliminate chimeric receptor-specific B cells in vivo.
We have previously performed extensive characterizations of the K b -CD28-z receptor, through studies in which the RMTC were targeting OT-1 T lymphocytes that recognize K b pulsed with ovalbumin 257-264 peptide rather than K b -specific B cells. 11, 25 To test whether the K b -CD28-z RMTC could similarly recognize chimeric receptor-specific B cells, we cocultured them with cells from 3-83 BCR Tg mice which incorporate a rearranged BCR specific for K b . 26 Like the HEL-specific receptor in To determine whether a similar resistance to soluble Ab was present in vivo, doses of up to 1 mg of 3-83 Ab were administered to sublethally irradiated B10.D2 mice. Syngeneic 3-83 splenocytes were 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) labeled to more readily distinguish them from residual endogenous B cells and transferred by retroorbital injection. Purified CD8 + RMTC were then transferred through the alternate retroorbital site. The mice were sacrificed at 48 h, the serum was analyzed for the presence of the infused Ab and spleen and lymph nodes (LNs) were assessed for the presence of residual 3-83 B cells.
As would be expected from the large dose of Ab administered and the pharmacokinetics and distribution of IgG in mice, studies of serum isolated from mice at the end of the 2-day experiment demonstrated levels of Ab capable of saturating the chimeric receptor on RMTC (data not shown). 27 In the absence of Ab, much as with the HEL-CD28-z RMTC, the K b -CD28-z RMTC efficiently eliminated the adoptively transferred, CFSE-labeled Tg B cells ( Figure 6 ). In contrast when MSCV vector-trans- (Figures 6b and c) . Therefore RMTC activity was specifically directed against the cognate, chimeric receptor-specific B-cell population.
Because the RMTC were GFP labeled in these experiments, they could also be visualized in treated mice. Although equal numbers of vector control and K b -CD28-z RMTC were administered in multiple experiments, consistently fewer (B1=3 in the experiment shown) K b -CD28-z RMTC were detected compared with vector-transduced control cells. This suggests that either there is an increased rate of K b -CD28-z RMTC death after transfer, potentially reflecting increased activationinduced cell death (AICD) of RMTC that have been stimulated by cognate B cells, or that these cells distribute to other unassessed organ locations after transfer. A similar observation was made in experiments using HEL-CD28-z RMTC.
The efficiency of the RMTC in targeting antigenspecific B cells in vitro and in vivo suggested that RMTC should be able to quell any B-cell response against the chimeric receptor. We tested this by analyzing whether the HEL-CD28-z RMTC could fully tolerize HEL-specific B cells in unmanipulated wild-type mice. The HEL system was selected for study rather than the K b system because it lacks the complications associated with infusing nonimmunosuppressed mice with cells expressing an allogeneic MHC molecule, K b . 28 In an attempt to fully eradicate chimeric receptor-specific B cells, we Redirected B cell-specific CTL P Nguyen et al adoptively transferred three successive doses of HEL-CD28-z RMTC into wild-type mice over 10 days. Preimmune serum was then obtained, the animals were immunized with HEL antigen and anti-HEL Ab response was followed. This was measured by staining chimeric receptor-or control vector-transduced RMTC with serum titrations. Using viable RMTC to measure the specific Ab response ensured that the titrations only measured Abs capable of binding native chimeric receptor on the RMTC. Unexpectedly, after HEL-CD28-z RMTC transfer but prior to HEL immunization, a significant Ab response was observed (Figure 7a left column, Figure 7b ). Chimeric receptor-specific Abs, in contrast were not observed in mice receiving control vector-transduced T cells or saline. By 2 weeks after primary immunization with HEL, this Ab response persisted in the HEL-CD28-z-treated mice and a new Ab response developed in mice treated with vector control RMTC or saline (Figure 7a right column, Figure 7c ). The Ab response in HEL-CD28-z-treated mice could not be distinguished from that in control-treated animals either at the 2 week time point, at later time points or even after secondary immunization (data not shown). Therefore adoptively transferred RMTC do not fully tolerize B cells to their chimeric receptor. To the contrary, they are able to provide an immunogenic source of HEL antigen through the chimeric receptor despite their ability to also selectively Redirected B cell-specific CTL P Nguyen et al eliminate cognate receptor-specific B lymphocytes. At least some B cells therefore escape the RMTC and these are then able to differentiate and produce antichimeric receptor-specific Abs.
Discussion
RMTC are currently being investigated in clinical trials as a possible immunotherapy for cancer and other diseases. The RMTC's chimeric receptor may serve as a neoantigen, capable of inducing an immune response. Simultaneously, CTL RMTC that engage B lymphocytes through their chimeric receptor should be stimulated and lyse the cognate, receptor-specific B lymphocytes. We demonstrate that either of two chimeric surrogate TCRs efficiently engage cognate, ligand-specific B cells, and that this interaction stimulates the RMTC. The RMTC proliferate, produce cytokines and most significantly lyse the B cells. Importantly, RMTC are able to eliminate receptor-specific B lymphocytes in vivo. Thus B cell-specific RMTC act in a manner predictable by numerous studies showing similar activity redirected against tumor cells, infected cells and T cells bearing antigen-specific TCR. 7, 9, 29 Paradoxically, despite their ability to efficiently kill chimeric receptor-specific B cells, RMTC ultimately induce immunity and not tolerance. RMTC transferred into wild-type mice provoke a specific Ab response against the chimeric receptor even in the absence of any alternative form of antigen exposure. There are several possible reasons for the immunogenicity of chimeric receptors. First, it has been demonstrated that the majority of in vitro expanded, adoptively transferred CTL rapidly die upon adoptive transfer. 30 As the transferred CTL are deprived of anti-apoptotic cytokines provided in culture, they become increasingly susceptible to cytokine withdrawal-induced apoptosis. RMTC that encounter target B cells will be activated through their chimeric receptor and may also undergo AICD. Dying RMTC will be rapidly consumed by the reticuloendothelial system, where their chimeric receptors may be re-presented and provide a stimulus for B and T cells recognizing the neoantigen. Thus a competition may ensue between the directly tolerogenic effect of the RMTC through their cytolytic activity, and the immunogenic effect of dead or dying RMTC. As the localization of the activated, transferred RMTC and antigen-specific B cells may not wholly overlap, there may be reservoirs of receptor-specific B lymphocytes that cannot be readily tolerized by the RMTC. Alternatively, RMTC that survive adoptive transfer may not lyse antigen-specific B cells efficiently enough, and residual cells that have been stimulated by the chimeric receptor, but have not been killed by the RMTC may be capable of differentiating into Ab-secreting cells. In either situation, as the B cell matures into an Ab-secreting plasma cell, it will downregulate its BCR and thus cease to be a target for RMTC. Thus there is likely a narrow window for RMTC to establish B-cell tolerance, and once a breakthrough response has developed it may be too late to fully restrict the response.
Interestingly, RMTC are similarly incapable of fully eradicating their target cells in other systems. Tumors may persist after treatment with RMTC.
14 When we have redirected RMTC against antigen-specific T lymphocytes, a small but significant residuum of responsive T cells was identified. 10 Nevertheless, whether RMTC are able to induce B-cell tolerance in other systems remains to be determined. ScFv-based chimeric receptors used for immunotherapy will likely have more similarity to self antigens than the HEL antigen used here, which is wholly foreign to the host and may therefore be more immunogenic. Further, RMTC may often be administered in patients receiving chemotherapeutics or other immunosuppressive agents that may limit the hostimmune response. It will therefore be important to assess the significance of antichimeric Ab formation in clinical circumstances.
One concern if an Ab response develops against the chimeric receptor is the ability of the Abs to competitively inhibit receptor function. This competition does not appear to significantly impact RMTC activity. Both in vitro and in vivo, receptor-specific Abs structurally identical to those expressed on target B cells were unable to block RMTC activity. This possibly reflects the high affinity between the chimeric receptor and its BCR ligand, and the mechanics of T-cell interactions with antigen presenting cells such as B cells. T and B cells initially engage each other through various adhesion receptors, not their antigen receptors. This could allow the RMTC to bind its target cell even in the presence of blocking chimeric receptor-specific Ab. As chimeric receptor turns over or bound Ab dissociates from receptor, the high local concentration of cell-associated ligand on the surface of the juxtaposed target B cell would be expected to outcompete soluble blocking Ab in binding the chimeric receptor, thereby stabilizing and activating the docked RMTC. Thus T and B-cell interactions through multiple receptor pairs, combined with the high chimeric receptor-BCR affinity may allow the RMTC to kill its target despite blocking Ab. This does not imply that the soluble Ab has no effect. Indeed, in studies of the redirected cytolysis of IGROV-1 cells by scFv-g-modified T lymphocytes, lysis was inhibited in a dose-dependent manner by anti-idiotypic Ab specific for the chimeric receptor. When anti-trinitrophenyl (TNP) scFv-g-modified T cells were used to target TNP-labeled Daudi cells, ligand-specific anti-TNP Ab was similarly able to inhibit redirected cytolysis. 31 The impact of Figure 4 Chimeric receptor-mediated stimulation of K b -CD28-z receptor-modified CTL. Control vector-or chimeric receptortransduced CTL (10 5 ) were stimulated with an equal number of either non-transgenic (Tg) or 3-83 BCR Tg-irradiated splenocytes. Interferon (IFN)-g production was determined at 24 h.
Redirected B cell-specific CTL P Nguyen et al antireceptor Abs may therefore be highly dependent on the characteristics of the Ab produced and the nature of the target cell interaction with the RMTC. Further studies will be needed to fully determine the consequences of such Abs. In summary we demonstrate that RMTC are highly effective at targeting antigen-specific B lymphocytes in vivo and in vitro. Despite this, they are not capable of fully inducing B-cell tolerance and to the contrary are capable of inducing a chimeric receptor-specific, Ab response. Receptor-specific Ab production may be of concern in the use of RMTC as a clinical therapy, and monitoring for the development of anti-RMTC immune responses should be considered in future clinical trials.
Materials and methods

Constructs
Synthesis of the K b -CD28-z construct has been described. 22 The HEL-CD28-z construct was similarly synthesized. Briefly, cDNA fragments encoding HEL, the leader, hinge and TM domains of murine CD8, and the cytoplasmic tails of CD28 and z were isolated by PCR from cDNA clones or splenic cDNA. Flanking restriction sites and the L-G mutation in CD28 (Figure 1a) were added to the fragments by PCR, and the fragments linked. Assembled constructs were subcloned into the MSCV-I-GFP retroviral vector 32 (gift of E Vanin) at its EcoRI and XhoI cloning sites. Redirected B cell-specific CTL P Nguyen et al
ImmunoResearch, West Grove, PA, USA); goat anti-rat IgG (Jackson ImmunoResearch), 145-2C11 hamster antimouse CD3e (Pharmingen) and 37.51 hamster antimouse CD28 (Pharmingen).
Retroviral transduction and T cell culture
Retrovirus was produced as described. 33 Briefly, 10 mg of chimeric receptor constructs and 10 mg of retrovirus helper DNA constructs were co-transfected into 293-T cells by calcium phosphate precipitation. At 16 h the cells were washed and cultured in Dulbecco's modified Eagles medium /10% fetal calf serum (FCS) for 48 h. Supernatant was collected twice daily and used to infect GP+E86 retroviral producer cells in the presence of 8 mg ml À1 polybrene. Transduced GP+E86 cells were flow cytometrically sorted for the presence of GFP and expanded. To transduce T lymphocytes, freshly isolated LN cells from C57BL/6, B10.D2 or OT-1 mice were depleted of B cells by panning on goat anti-mouse IgGcoated plates and stimulated with soluble CD3-and CD28-specific Abs. Alternatively whole splenocytes were stimulated with conA. A total of 2 ng ml À1 rmIL-2 (R&D Systems, Minneapolis, MN, USA) or 10 U ml À1 rhIL-2 (NCI BRB Repository, Frederick, MD, USA) was added to the cultures. Medium was removed after 2 days and replaced with cleared supernatant from the GP+E86 retroviral producer cells with 8 mg ml À1 polybrene and rIL-2 and the cells were spun at 1800 r.p.m. for 90 min in a Jouan CR422 tabletop centrifuge. A second cycle of spin infection was repeated on day 3. Transduced T cells were flow cytometrically sorted on day 4-5 for expression of GFP and CD8 and expanded by culturing in EHAA medium (Biosource International, Camarillo, CA, USA)/ 10% FCS in the presence of rIL-2 for 5 days. The cells were restimulated every 7-10 days using 2 mg ml À1 conA, 2 Â 10 6 per ml 3000 rad-irradiated syngeneic splenocytes and rIL-2 for a maximum of two cycles. Transduced cells were washed and assayed 4-6 days after stimulation unless otherwise indicated. Assays were performed in the absence of exogenously added IL-2.
Proliferation analysis
The designated number of resting RMTC were cultured with 2.5 Â 10 5 of the indicated irradiated splenocyte Figure 7 Transferred hen egg lysozyme (HEL)-modified CTL induce a HEL-specific Ab response. 10 7 HEL-CD28-z or control vectortransduced CTL were adoptively transferred into cohorts of C57BL/6 mice on days -9, -6, and -3. Alternatively, an equal volume of phosphate-buffered saline (PBS) was administered at those time points. On day 0 pre-immune serum was isolated and the mice were then immunized with HEL in CFA. Serum was isolated again 2 weeks following immunization. (a) Sample flow cytometry plots demonstrating staining of GFP + HEL chimeric receptor-modified CTL with serum obtained at d0 or d14 from the treated mice. Serum samples were added to the cells at a 1:60 dilution, followed with PE-labeled goat anti-mouse Ig. (b) Serum titrations were performed on the HEL expressing RMTC as in (a) using day 0 serum. Geometric mean fluorescence intensity is plotted vs serum titration for individual mice. In addition, results from controls to which no serum was added (21 Ab) or where a 1:30 titration of serum was tested against murine stem cell virus(MSCV) vectortransduced CTL are plotted. (c) Serum from the day 14 time point was titrated and results plotted as in (b).
Redirected B cell-specific CTL P Nguyen et al population. After 2 days, the cells were pulsed with 1 mCi 3 H-thymidine for 16 h and harvested onto filtermats (Wallac-Perkin Elmer, Waltham, MA, USA). Proliferation was measured by liquid scintillation counting of incorporated 3 H. All samples were analyzed in triplicate.
Cytokine analysis
Cultures were established as for proliferation analysis. A total of 50 ml of culture supernatant was removed and IFN-g concentration was measured by BioPlex analysis (Bio-Rad, Hercules, CA, USA) after 48 h.
In vitro cytotoxicity assay
RMTC (10 5 ), day 4-6 poststimulation, were incubated with a 1:1 or the designated ratio of splenocyte target cells for 4-6 h. Target cells typically contained B50% B lymphocytes. At the end of the culture 5000-10 000 6 mm fluorescent TruCount beads (BD Biosciences, Duarte, CA, USA) were added. Samples were stained for the indicated target B-cell population and then analyzed by quantitative flow cytometry. A preestablished TruCount bead event number was run to ensure that equivalent proportions of each sample were enumerated. Viable cell counts are plotted for individual samples assayed in triplicate.
Adoptive transfer analyses
RMTC (B10 7 ) and MD-4 or 3-83 ( 10 7 ) splenocytes were separately transferred into Rag À/À or 450 rad-irradiated B10.D2 mice via retroorbital injection (through contralateral orbits). After 2 days, spleens and/or LNs were collected and single cell suspensions made. Red blood cells were lysed, cells were washed two times with Hank's buffered salt solution (HBSS) and then stained for the presence of Ag-specific B lymphocytes as described in the text. For labeling with CFSE (Molecular Probes, Carlsbad, CA, USA), splenocytes were harvested, washed and labeled with 5 mM CFSE for 7 min at 37 1C. The cells were washed three times with phosphatebuffered saline prior to adoptive transfer.
Flow cytometry
Analyses were performed on a FACScalibur (BD Biosciences) using Cellquest software (BD Biosciences) and sorting on a MoFlo cytometer (Dako Cytomation, Fort Collins, CO, USA)
Statistics
Figures shown are representative of X3 experiments except Figures 2 and Ab treatments in Figure 6 , which are of two experiments. Standard deviations and t-tests were performed using excel software. Data points show means71 s.d.
